An observational study in Critical Ischemia Limb, sponsored by University Hospital, Angers. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by University Hospital, Angers · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Chronic Limb-Threatening Ischemia with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · France.
Among the 22 studies in Chronic Limb-Threatening Ischemia with a site in France, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2025, is one of 11 observational ones, and was the 15th registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →7 of the 22 studies in Chronic Limb-Threatening Ischemia with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier le Mans · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Fondation Hôpital Saint-Joseph · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 40+
University Hospital, Bordeaux · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4
First in 2007; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 200 is above the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 50 across the 11 interventional studies, 300 across the 11 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
University Hospital, Angers is the lead sponsor of 481 studies on the registry; 122 are open to participants now.
University Hospital, Angers has 3 studies filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Limb-Threatening Ischemia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238050University Hospital, AngersNOrmoBaric Oxygen Therapy Use In Critical Limb ISchemia | 2026-12 |
| NCT07014072University Hospital, BordeauxComprehensive Limb Evaluation and Arterial Revascularization With Toe Pressure Optimization Registry | 2027-07-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Chronic Limb-Threatening Ischemia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Peripheral arteriopathy disease (PAD) affects 1 million people in France. In its most advanced stage: chronic permanent ischemia also called critical ischemia, the prognosis of patients is burdened with a one-year mortality rate of 30%. Chronic permanent ischemia results from a lack of oxygen supply to the microcirculatory network, responsible for tissue death and the development of trophic disorders. In this context, many studies have focused on the contribution of hyperbaric oxygen therapy, however none demonstrates with certainty its beneficial effect with a heavy set-up for teams and patients. Furthermore, it appears that normobaric oxygen therapy could have its place in this context by temporarily restoring a sufficient level of transcutaneous oxygen. However, even if normobaric oxygen therapy is common practice although empirical for some practitioners, no data demonstrates its real interest. The purpose of this study is therefore to report the proportion, in usual practice, of patients with permanent chronic ischemia of the lower limb(s), benefiting from normobaric oxygen therapy, but also to show the interest of the contribution of this therapy in usual comprehensive management of these patients. This is a pilot study, after which, if the hypothesis is confirmed, it may be proposed to carry out a randomized study, on a large scale, in order to validate the use of normobaric oxygen therapy in the context of chronic permanent ischemia.
In arterial pathology of the lower limbs at the stage of chronic permanent ischemia, very few data exist on the benefit of normobaric oxygen therapy in these patients. The purpose of the present study is to report the proportion in usual practice of patients benefiting from normobaric oxygen therapy and to show the interest of the contribution of this therapy in the usual global management of patients presenting with chronic permanent ischemia of the lower limbs.
Regarding the Wound, Ischemia, Foot Infection Score (WIfI score), it includes three sub-parts, each of which has a specific evaluation grid scoring between 0 and 3. From this evaluation grid, an overall score can be calculated with different interpretations to determine the risk of amputation at one year as well as the probability of improvement in the event of revascularization, ranging from very low risk to high risk. Nevertheless, the overall evaluation of the score could mask a significant improvement in one of the items evaluated, impacting the clinical management and the future of the patient. This is why, during this study, the improvement of each item of the WIfI score separately will be studied.
The hypothesis is that putting patients in chronic permanent ischemia on oxygen therapy, which is performed frequently, brings a medical benefit compared to patients who do not benefit from it.
hospitalized patient with symptoms of chronic permanent ischemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
hospitalized patients suspected of chronic permanent ischemia realizing transcutaneous oxymetry are enroled in the study. The WIfI score is calculated at the inclusion.
Procedure: introduction of oxygen therapy or not
During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
Comparison of clinical characteristics of patients, whether or not they benefit from oxygen therapy in usual practices.
Determination of patients' characteristic with or without a prescription of oxygen therapy to inventorized clinical practices.
Time frame: 6 months
Comparison of biological characteristics of patients, whether or not they benefit from oxygen therapy in usual practices.
Determination of patients' characteristics with or without a prescription of oxygen therapy to inventorized clinical practices.
Time frame: 6 months
Collection of all investigations carried out since inclusion and all modifications of medical therapy or implementation of surgical treatment.
Descriptive study of investigations and therapies (medical and surgical) carried out during the patient's follow-up period
Time frame: 6 months
prevalence of decision-making parameters by using the sheet sent to the prescribing doctor by the patient.
Descriptive study of the parameter(s) which allowed the prescriber to make the decision to implement oxygen therapy.
Time frame: 6 months
difference in the WIfI score items at inclusion and at 6 months.
Evaluation of the evolution of chronic permanent ischemia according to the administration in current practice of normobaric oxygen therapy.
Time frame: 6 months
All-cause mortality at 6 months.
Evaluation of the evolution of chronic permanent ischemia according to the administration in current practice of normobaric oxygen therapy.
Time frame: 6 months
occurrence of an amputation between one week after inclusion and 6 months.
Evaluation of the evolution of chronic permanent ischemia according to the administration in current practice of normobaric oxygen therapy.
Time frame: 6 months
difference in score obtained at 1 month and at 6 months depending on the presence of chronic permanent ischemia or not and the administration of oxygen or not.
Assessment of the quality of life of patients suspected of chronic permanent ischemia using the Vascu-QOL-6 questionnaire
Time frame: 1 and 6 month
Proportion of compliant patients in whom oxygen was prescribed on an outpatient basis
Evaluation of compliance with oxygen for patients benefiting from it
Time frame: 1 and 6 month
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 20 months is below that.
Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →